Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function. - Effect of Tredaptive on serum lipoproteins and inflammatory markers

• Conditions: Hypercholesterolaemia.

• Registration Number: EUCTR2010-018531-17-GB
• Lead Sponsor: Central Manchester University Hospitals NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-03-18
• Last Update Posted: 25 September 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Men and women who are taking cholesterol-lowering medication (maximum tolerated statins and/or ezetimibe) and who have not reached the recommended LDL target of less than 1.8 mmol/l (70 mg/l). Ezetimibe will be stopped 4 weeks before entering the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Pregnant and/or breast-feeding women.
Significant renal impairment (eGFR < 59ml/min).
Active liver disease and transaminases > 3 times upper limit of normal range.
Patients on fibrates.
Patients on Omacor.
Patients who are allergic to nicotinic acid.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified